Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Significant progress has been made in prospectively designing molecules using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the analysis reported herein of a second wave of drug candidates that originated after the development and implementation of this tool. This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochemical properties. The CNS MPO tool has helped to increase the percentage of compounds nominated for clinical development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA). The use of this tool has played a role in reducing the number of compounds submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicology into First in Human studies. Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compounds nominated for clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
In the citing paper
“Clearly, molecular weight is a physicochemical parameter fundamental for CNS penetration and for the overall profile of drugs against neurodegenerative diseases.103,104”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Self-citationPhysiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Self-citationCNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
Self-citationGhose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Feng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., & de Morais, S. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017434 · Cited by 440
Development of a new permeability assay using low‐efflux MDCKII cells
Di, L., Whitney‐Pickett, C., Umland, J. P., Zhang, H., Zhang, X., Gebhard, D. F., Lai, Y., Federico, J. J., Davidson, R. E., Smith, R., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22674 · Cited by 313
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300
Ertl, P. (2007) · Methods and principles in medicinal chemistry · doi:10.1002/9783527621286.ch5 · Cited by 75
Research works printed but not linked: 1
- Harrington, E. C., Jr. (1965) The desirability function. Indust. Qual. Control 21, 494-498.
Cited by
Drug discovery with explainable artificial intelligence
Jiménez-Luna, J., Grisoni, F., & Schneider, G. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-00236-4 · Cited by 1,063
GuacaMol: Benchmarking Models for de Novo Molecular Design
Brown, N., Fiscato, M., Segler, M. H. S., & Vaucher, A. C. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00839 · Cited by 895
A non-hallucinogenic psychedelic analogue with therapeutic potential
Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., McCarroll, M. N., Taylor, J. C., Myers-Turnbull, D., et al. (2021) · Nature · doi:10.1038/s41586-020-3008-z · Cited by 473
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 445
The Synthesizability of Molecules Proposed by Generative Models
Gao, W., & Coley, C. W. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00174 · Cited by 394
The Blood–Brain Barrier (BBB) Score
Gupta, M., Lee, H. J., Barden, C. J., & Weaver, D. F. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01220 · Cited by 332
Hydrogen-Bond Donors in Drug Design
Kenny, P. W. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01147 · Cited by 241
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
Lin, G. L., Wilson, K. M., Ceribelli, M., Stanton, B. Z., Woo, P. J., Kreimer, S., Qin, E. Y., Zhang, X., Lennon, J., Nagaraja, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw0064 · Cited by 234
“We generated †The CNS MPO scores are based on the design algorithm defined by Wager et al. ( 18 ).”
InfluentialXiong, B., Wang, Y., Chen, Y., Xing, S., Liao, Q., Chen, Y., Li, Q., Li, W., & Sun, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00910 · Cited by 232
Overview of Recent Strategic Advances in Medicinal Chemistry
Wu, G., Zhao, T., Kang, D., Zhang, J., Song, Y., Namasivayam, V., Kongsted, J., Pannecouque, C., De Clercq, E., Poongavanam, V., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00359 · Cited by 181
Enhancing preclinical drug discovery with artificial intelligence
Vijayan, R. S. K., Kihlberg, J., Cross, J. B., & Poongavanam, V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.023 · Cited by 180
“117 121 In addition, the establishment of miniaturized, high-throughput in vitro ADMET pro fi ling assays resulted in the parallel evaluation of ef fi cacy and ADMET during earlier stages of drug discovery.”
MethodAlbertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
“neurodegenerative diseases.(103,104) Furthermore, the single‐molecule pharmacokinetic profile of hybrids, from”
BackgroundTarget-Based Evaluation of “Drug-Like” Properties and Ligand Efficiencies
Leeson, P. D., Bento, A. P., Gaulton, A., Hersey, A., Manners, E. J., Radoux, C. J., & Leach, A. R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00416 · Cited by 176
“For example, drugs acting in the central nervous system 48,49 have lower MW than anti-infective compounds, 50,51 as expected, and their corresponding target comparators also show the same differences (Supporting Figure S3).”
Loryan, I., Reichel, A., Feng, B., Bundgaard, C., Shaffer, C., Kalvass, C., Bednarczyk, D., Morrison, D., Lesuisse, D., Hoppe, E., et al. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03246-6 · Cited by 142
Tinworth, C. P., & Young, R. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01596 · Cited by 141
D’Aloisio, V., Dognini, P., Hutcheon, G. A., & Coxon, C. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.019 · Cited by 123
Mignani, S. M., Rodrigues, J., Tomás, H., Jalal, R., Singh, P. P., Majoral, J., & Vishwakarma, R. A. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.010 · Cited by 133
Zhang, P., Park, H.-J., Zhang, J., Junn, E., Andrews, R. J., Velagapudi, S. P., Abegg, D., Vishnu, K., Costales, M. G., Childs‐Disney, J. L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905057117 · Cited by 127
Pallesen, J. S., Tran, K. T., & Bach, A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00358 · Cited by 103
DNA-encoded libraries (DELs): a review of on-DNA chemistries and their output
Shi, Y., Wu, Y., Yu, J., Zhang, W., & Zhuang, C. (2021) · RSC Advances · doi:10.1039/d0ra09889b · Cited by 120
The Critical Role of Passive Permeability in Designing Successful Drugs
Di, L., Artursson, P., Avdeef, A., Benet, L. Z., Houston, J. B., Kansy, M., Kerns, E. H., Lennernäs, H., Smith, D. A., & Sugano, K. (2020) · ChemMedChem · doi:10.1002/cmdc.202000419 · Cited by 119
Gotta be SAFE: a new framework for molecular design
Noutahi, E., Gabellini, C., Craig, M. J., Lim, J. S. C., & Tossou, P. (2024) · Digital Discovery · doi:10.1039/d4dd00019f · Cited by 117
Ackloo, S., Al-awar, R., Amaro, R. E., Arrowsmith, C. H., Azevedo, H., Batey, R. A., Bengio, Y., Betz, U. A. K., Bologa, C. G., Chodera, J. D., et al. (2022) · Nature Reviews Chemistry · doi:10.1038/s41570-022-00363-z · Cited by 112
Human Positron Emission Tomography Neuroimaging
Hooker, J. M., & Carson, R. E. (2019) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-062117-121056 · Cited by 91
Occurrence of Morpholine in Central Nervous System Drug Discovery
Lenci, E., Calugi, L., & Trabocchi, A. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00729 · Cited by 105
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
Lin, Y.-H., Satani, N., Hammoudi, N., Yan, V. C., Barekatain, Y., Khadka, S., Ackroyd, J. J., Georgiou, D. K., Pham, C.-D., Arthur, K., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00313-3 · Cited by 91
Das, U. (2025) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2025.100213 · Cited by 106
Rankovic, Z. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01469 · Cited by 91
RetractedDunlap, L. E., Azinfar, A., Ly, C., Cameron, L. P., Viswanathan, J., Tombari, R. J., Myers-Turnbull, D., Taylor, J. C., Grodzki, A. C., Lein, P. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01404 · Cited by 95
Rabal, O., Sánchez-Arias, J. A., Cuadrado-Tejedor, M., de Miguel, I., Pérez-González, M., García-Barroso, C., Ugarte, A., Estella-Hermoso de Mendoza, A., Sáez, E., Espelosin, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00908 · Cited by 87
GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways
Demuro, S., Martino, R. M. C. D., Ortega, J. A., & Cavalli, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169098 · Cited by 92
“An additional approach toward assessment of drug-likeness properties affecting overall brain permeability and very useful in prioritizing lead candidates consists in the Pfizer’s CNS multiparameter optimization [10], which takes into account calculated partition coefficient (ClogP), calculated distribution coefficient…”
BackgroundChallenges and Opportunities in Central Nervous System Drug Discovery
Danon, J. J., Reekie, T. A., & Kassiou, M. (2019) · Trends in Chemistry · doi:10.1016/j.trechm.2019.04.009 · Cited by 89
Neumaier, F., Zlatopolskiy, B. D., & Neumaier, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101542 · Cited by 86
“As described in more detail elsewhere [103,107,108], multi-parameter optimization (MPO) approaches can be used to obtain a single weighted score (CNS MPO or CNS PET MPO score) that incorporates all of these physicochemical properties.”
MethodThe rise and rise of protein degradation: Opportunities and challenges ahead
Hughes, S. J., Testa, A., Thompson, N., & Churcher, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.006 · Cited by 76
Classics in Chemical Neuroscience: Memantine
Alam, S., Lingenfelter, K. S., Bender, A. M., & Lindsley, C. W. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00270 · Cited by 73
Kozikowski, A. P., Shen, S., Pardo, M., Tavares, M. T., Szarics, D., Benoy, V., Zimprich, C., Kutil, Z., Zhang, G., Bařinka, C., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00600 · Cited by 83
Fischer, W. H., Currais, A. J. M., Liang, Z., Pinto, A. F. M., & Maher, P. A. (2018) · Redox Biology · doi:10.1016/j.redox.2018.101089 · Cited by 84
“Strikingly, sterubin meets the desirable physicochemical criteria to be a viable CNS drug candidate (Table 3), and it has a higher score of CNS druglikeness than fisetin [49].”
BackgroundJordan, C. J., Cao, J., Newman, A. H., & Xi, Z. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.04.015 · Cited by 79
“The development of the Multiparameter Optimization (MPO) algorithm to predict CNS penetration has improved prioritization of clinical candidates in drug development (Wager et al., 2010a; Wager et al., 2010b; Wager et al., 2016).”
MethodLiang, Z., Currais, A. J. M., Soriano‐Castell, D., Schubert, D. A., & Maher, P. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107749 · Cited by 77
Zorbaz, T., Braïki, A., Maraković, N., Renou, J., la Mora, E. D., Hrvat, N. M., Katalinić, M., Silman, I., Sussman, J. L., Mercey, G., et al. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201801394 · Cited by 76
Profiling donepezil template into multipotent hybrids with antioxidant properties
Mezeiova, E., Spilovska, K., Nepovimova, E., Gorecki, L., Soukup, O., Dolezal, R., Malinak, D., Janockova, J., Jun, D., Kuca, K., et al. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1443326 · Cited by 70
Multi-objective optimization methods in novel drug design
Lambrinidis, G., & Tsantili‐Kakoulidou, A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1867095 · Cited by 71
“bond donor and acceptor sites and basic pKa [58,59].”
BackgroundDiscovery of potent inhibitors of α-synuclein aggregation using structure-based iterative learning
Horne, R. I., Andrzejewska, E. A., Alam, P., Brotzakis, Z. F., Srivastava, A., Aubert, A., Nowinska, M., Gregory, R. C., Staats, R., Possenti, A., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01580-x · Cited by 72
Rook, J. M., Bertron, J. L., Cho, H. P., García-Barrantes, P. M., Moran, S. P., Maksymetz, J., Nance, K. D., Dickerson, J. W., Remke, D. H., Chang, S., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00131 · Cited by 71
McLachlan, T., Matthews, W. C., Jackson, E. R., Staudt, D. E., Douglas, A. M., Findlay, I. J., Persson, M. L., Duchatel, R. J., Mannan, A., Germon, Z. P., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0567 · Cited by 71
“Abbreviations: CNS MPO, central nervous systemmultiparameter optimization, score ranges from 0 to 6, higher than 4 aims to predict CNS penetration ability (97);”
BackgroundComputer-Aided Drug Discovery and Design: Recent Advances and Future Prospects
Talevi, A. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3441-7_1 · Cited by 69
Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor
Shraga, A., Olshvang, E., Davidzohn, N., Khoshkenar, P., Germain, N., Shurrush, K., Carvalho, S., Avram, L., Albeck, S., Unger, T., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.10.011 · Cited by 64
Tumwesigye, K. S., Sousa, A. R., OLIVEIRA, J. C., & Sousa-Gallagher, M. J. (2017) · Food Packaging and Shelf Life · doi:10.1016/j.fpsl.2017.04.007 · Cited by 67
Computational Chemistry on a Budget: Supporting Drug Discovery with Limited Resources
Willems, H. M. G., Cesco, S. D., & Svensson, F. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02126 · Cited by 65
“The latter two properties are needed to calculate a CNS MPO score, 29 which prioritizes ligands likely to penetrate the blood-brain barrier and is therefore an important filter for CNS projects.”
BackgroundYu, T.-H., Su, B., Battalora, L. C., Liu, S., & Tseng, Y. J. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab377 · Cited by 64
Altman, R. A., Sharma, K. K., Rajewski, L. G., Toren, P. C., Baltezor, M. J., Pal, M., & Karad, S. N. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00085 · Cited by 63
Human-in-the-loop assisted de novo molecular design
Sundin, I., Voronov, A., Xiao, H., Papadopoulos, K., Bjerrum, E. J., Heinonen, M., Patronov, A., Kaski, S., & Engkvist, O. (2022) · Journal of Cheminformatics · doi:10.1186/s13321-022-00667-8 · Cited by 63
Improvement in aqueous solubility achieved via small molecular changes
Walker, M. A. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.09.041 · Cited by 60
Jing, L., Wu, G., Kang, D., Zhou, Z., Song, Y., Liu, X., & Zhan, P. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.012 · Cited by 60
Sharma, S., Zhang, Y., Akter, K. A., Nozohouri, S., Archie, S. R., Patel, D., Villalba, H., & Abbruscato, T. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051357 · Cited by 58
“A desirable PC value for a compound is one of the major prerequisites in vitro ADME properties for a potential CNS drug [45,46].”
BackgroundAleo, M. D., Shah, F., Allen, S. W., Barton, H. A., Costales, C., Lazzaro, S., Leung, L. Y., Nilson, A. L., Obach, R. S., Rodrigues, A. D., et al. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00262 · Cited by 58
Graph-based molecular Pareto optimisation
Verhellen, J. (2022) · Chemical Science · doi:10.1039/d2sc00821a · Cited by 57
Khan, T., Lawrence, A. J., Azad, I., Raza, S., Joshi, S., & Khan, A. R. (2019) · Current Computer - Aided Drug Design · doi:10.2174/1573399815666190326120006 · Cited by 57
Combining Machine Learning and Molecular Dynamics to Predict P‑Glycoprotein Substrates
Esposito, C., Wang, S., Lange, U. E. W., Oellien, F., & Riniker, S. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00525 · Cited by 57
Assessing molecular scaffolds for CNS drug discovery
Mayol-Llinàs, J., Nelson, A. S., Farnaby, W., & Ayscough, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.008 · Cited by 55
Odi, R., Bibi, D., Wager, T. T., & Bialer, M. (2020) · Epilepsia · doi:10.1111/epi.16597 · Cited by 55
Self-citationPI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma
Duchatel, R. J., Jackson, E. R., Parackal, S., Kiltschewskij, D. J., Findlay, I. J., Mannan, A., Staudt, D. E., Thomas, B. C., Germon, Z. P., Laternser, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170329 · Cited by 55
“To identify the best strategy to test in orthotopic DIPG models, we assessed the potential of each drug to penetrate the brain using CNS multi-parameter optimization (MPO) (45) and correlated predicted CNS penetration with paxalisib synergism.”
MethodLiang, Z., & Li, Q. X. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00010 · Cited by 54
Tong, Y., Zhang, P., Yang, X., Liu, X., Zhang, J., Grudniewska, M., Jung, I., Abegg, D., Liu, J., Childs‐Disney, J. L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2306682120 · Cited by 53
“The CNS - MPO score takes into account: i) lipophilicity (cLogP); ii) calculated distribution coefficient at pH 7.4 (cLogD); iii) molecular weight (MW); iv) topological polar surface area (TPSA); v) the number of hydrogen - bond donors (HBDs); and vi) the most basic center (pK a ) (47).”
BackgroundMethodInfluentialKim, M., Laramy, J. K., Mohammad, A. S., Talele, S., Fisher, J. E., Sarkaria, J. N., & Elmquist, W. F. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084210 · Cited by 53
Amporndanai, K., Rogers, M., Watanabe, S., Yamanaka, K., O’Neill, P. M., & Hasnain, S. S. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102980 · Cited by 53
Drilon, A., Horan, J. C., Tangpeerachaikul, A., Besse, B., Ou, S.-H. I., Gadgeel, S. M., Camidge, D. R., van der Wekken, A. J., Nguyen-Phuong, L., Acker, A., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0968 · Cited by 52
“5 was derived, consistent with the potential for brain penetrance and activity (38).”
BackgroundOrexin supplementation in narcolepsy treatment: A review
Nepovimová, E., Janočková, J., Misík, J., Kubík, Š., Stuchlík, A., Valeš, K., Korábečný, J., Mezeiová, E., Doležal, R., Soukup, O., et al. (2018) · Medicinal Research Reviews · doi:10.1002/med.21550 · Cited by 51
Chen, Z., Mori, W., Deng, X., Cheng, R., Ogasawara, D., Zhang, G., Schafroth, M. A., Dahl, K., Fu, H., Hatori, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01778 · Cited by 50
Suri, A., Bailey, A. W., Tavares, M. T., Gunosewoyo, H., Dyer, C., Grupenmacher, A. T., Piper, D. R., Horton, R. A., Tomita, T., Kozikowski, A. P., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092112 · Cited by 50
“This pioneering observation was updated and extended to undisclosed internal CNS candidates within Pfizer as well approved CNS drugs [79,80].”
BackgroundDARK Classics in Chemical Neuroscience: Phencyclidine (PCP)
Bertron, J. L., Seto, M., & Lindsley, C. W. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00266 · Cited by 49
Bos, P. H., Houang, E. M., Ranalli, F., Leffler, A. E., Boyles, N. A., Eyrich, V. A., Luria, Y., Katz, D., Tang, H., Abel, R., et al. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00072 · Cited by 49
Gupta, M., Feng, J., & Bhisetti, G. (2024) · Molecules · doi:10.3390/molecules29061264 · Cited by 48
“However, a follow-up study involving re-examining the MPO score by the authors suggested that the MPO score can vary substantially depending on the computational software and method used to calculate physiochemical properties (mainly LogD and pKa) [27].”
MethodTuning Properties for Blood–Brain Barrier Permeation: A Statistics-Based Analysis
Dichiara, M., Amata, B., Turnaturi, R., Marrazzo, A., & Amata, E. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00541 · Cited by 47
Essential Medicinal Chemistry of Essential Medicines
Serafini, M., Cargnin, S., Massarotti, A., Pirali, T., & Genazzani, A. A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00415 · Cited by 46
Montoya, M. C., DiDone, L., Heier, R. F., Meyers, M. J., & Krysan, D. J. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00157 · Cited by 46
“Wager and coworkers at Pfizer have developed a scoring function that predicts assessment of potential of compounds to be developed as CNS drugs.(23) They have termed this”
da Rocha, M. N., da Fonseca, A. M., Dantas, A. N. M., dos Santos, H. S., Marinho, E. S., & Marinho, G. S. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00748-5 · Cited by 45
“In 2016, Wager et al., [54] observed that new CNS-active drug candidates had a low incidence of in vivo toxicity when they had low lipophilicity (logP 3), in a polarity range greater than 20–40 Å 2 .”
Correia, S. S., Iyengar, R. R., Germano, P., Tang, K., Bernier, S. G., Schwartzkopf, C. D., Tobin, J. V., Lee, T. W.-H., Liu, G., Jacobson, S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.656561 · Cited by 44
Bryostatin-1: a promising compound for neurological disorders
Tian, Z., Lu, X.-T., Jiang, X., & Tian, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1187411 · Cited by 43
Brain penetrant kinase inhibitors: Learning from kinase neuroscience discovery
Shi, Y., & Mader, M. M. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.007 · Cited by 43
Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma
Svec, R. L., Furiassi, L., Skibinski, C. G., Fan, T. M., Riggins, G. J., & Hergenrother, P. J. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00864 · Cited by 43
Ghose, A. K., Ott, G. R., & Hudkins, R. L. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00273 · Cited by 43
The Development of a Weighted Index to Optimise Compound Libraries for High Throughput Screening
Eurtivong, C., & Reynisson, J. (2018) · Molecular Informatics · doi:10.1002/minf.201800068 · Cited by 42
Luo, G., Chen, L., Kostich, W. A., Hamman, B. D., Allen, J., Easton, A. E., Bourin, C., Gulianello, M., Lippy, J., Nara, S. J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02131 · Cited by 42
Computational Modeling of Pharmaceuticals with an Emphasis on Crossing the Blood–Brain Barrier
Alves, P. A., Camargo, L. C., de Souza, G. M., Mortari, M. R., & Homem-de-Mello, M. (2025) · Pharmaceuticals · doi:10.3390/ph18020217 · Cited by 41
“Analyzing these parameters involves evaluating the parameter value “de-sirability”, i.e., the best range of values typically present in SNC drugs [57–59].”
Lin, C.-T., Lecca, D., Yang, L.-Y., Luo, W., Scerba, M. T., Tweedie, D., Huang, P.-S., Jung, Y.-J., Kim, D. S., Yang, C.-H., et al. (2020) · eLife · doi:10.7554/elife.54726 · Cited by 38
Kettle, J. G., Bagal, S. K., Barratt, D. G., Bodnarchuk, M. S., Boyd, S., Braybrooke, E. L., Breed, J., Cassar, D. J., Cosulich, S. C., Davies, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00746 · Cited by 40
NIR-II Engineered Exosome Nanotheranostic Probes for “Oriented Blasting” in Orthotopic Glioblastoma
Yu, D., Ding, Q., Xiang, C., Wang, D., Hu, L., Wang, J., Qian, K., Cheng, Z., & Li, Z. (2025) · ACS Nano · doi:10.1021/acsnano.5c01541 · Cited by 40
Rand, D., Ravid, O., Atrakchi, D., Israelov, H., Bresler, Y., Shemesh, C., Omesi, L., Zaltsman, S. L., Gosselet, F., Maskrey, T. S., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030311 · Cited by 39
“6 for JP4-039 [52], which places this candidate in the upper cohort for drug-like properties, suggesting a desirable alignment of ADME attributes, blood−brain barrier crossing, and lower-risk safety profile.”
BackgroundPretargeted imaging beyond the blood–brain barrier
Shalgunov, V., van den Broek, S. L., Andersen, I. V., Vázquez, R. G., Raval, N. R., Palner, M., Mori, Y., Schäfer, G. G., Herrmann, B., Mikula, H., et al. (2023) · RSC Medicinal Chemistry · doi:10.1039/d2md00360k · Cited by 40
Jackson, E. R., Persson, M. L., Fish, C. J., Findlay, I. J., Mueller, S., Nazarian, J., Hulleman, E., van der Lugt, J., Duchatel, R. J., & Dun, M. D. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad144 · Cited by 39
Drugging DNA Damage Repair Pathways for Trinucleotide Repeat Expansion Diseases
Benn, C., Gibson, K. R., & Reynolds, D. S. (2020) · Journal of Huntington s Disease · doi:10.3233/jhd-200421 · Cited by 39
“4 (cLogD); 3) molecular weight (MW); 4) topological polar surface area (TPSA); 5) number of hydrogen bond donors (HBD); 6) most basic centre (pKa) [66].”
BackgroundYang, Y.-T., Zhang, Y., Ma, M., Liu, H., Ge, K., Zhang, C., Jin, M., Liu, D., Wang, S., Yin, C., et al. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03390 · Cited by 38
Fontana, I. C., de Souza, D. G., Souza, D. O., Gee, A. D., Zimmer, E. R., & Bongarzone, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01572 · Cited by 39
de Oliveira, V. M., da Rocha, M. N., Roberto, C. H. A., Lúcio, F. N. M., Marinho, M. M., Marinho, E. S., & de Morais, S. M. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.137453 · Cited by 37
Challenges with multi-objective QSAR in drug discovery
Lambrinidis, G., & Tsantili-Kakoulidou, A. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1496079 · Cited by 35
“5 The six properties include calculated partition and distribution coefficients (clogP, clogD), MW, topological polar surface area (TPSA), HBD and HBA, and basic pKa [34].”
BackgroundChemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system
Bolaender, A., Zatorska, D., He, H., Joshi, S., Sharma, S., Digwal, C. S., Patel, H. J., Sun, W., Imber, B. S., Ochiana, S. O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24821-2 · Cited by 37
Recent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders
Jůza, R., Musílek, K., Mezeiová, E., Soukup, O., & Korábečný, J. (2022) · Medicinal Research Reviews · doi:10.1002/med.21923 · Cited by 37
Bayesian Optimization in Drug Discovery
Colliandre, L., & Muller, C. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3449-3_5 · Cited by 37
Metadata
- Authors
- Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Wager, Travis T.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-03-18
- Volume
- 7
- Issue
- 6
- Pages
- 767-775
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2300160852
- Cited by
- 653
- References
- 13
- Citations by year
- 2026: 104 · 2025: 121 · 2024: 103 · 2023: 75 · 2022: 72 · 2021: 45 · 2020: 37 · 2019: 32 · 2018: 40 · 2017: 19 · 2016: 5
- FWCI
- 30.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- ACS Chemical Neuroscience (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- desirability function, drug candidate design, ADME properties, blood-brain barrier permeability, ClogP, topological polar surface area, drug safety, drug discovery
- MeSH terms
- Algorithms, Animals, Biological Transport, Blood-Brain Barrier, Central Nervous System, Humans, Permeability, Drug Design, ATP Binding Cassette Transporter, Subfamily B, Member 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.